Sugi Predict

Sugi Predict / Compounds / SCHEMBL3353284

SCHEMBL3353284

SCHEMBL3353284

NC(=O)CCC(=O)Nc1ccccc1

nearest known ligand 0.72

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ L3MBTL1 Q9Y468 2/20 0.72
▸ MAPT P10636 2/20 0.61
▸ HTT P42858 1/20 0.61
▸ SMN1; SMN2 Q16637 1/20 0.61
▸ KDM1A O60341 1/20 0.59
▸ HDAC4 P56524 7/20 0.59
▸ HDAC1 Q13547 7/20 0.59
▸ HDAC7 Q8WUI4 7/20 0.59
▸ HDAC11 Q96DB2 7/20 0.59
▸ HDAC8 Q9BY41 7/20 0.59
▸ HDAC6 Q9UBN7 7/20 0.59
▸ HDAC9 Q9UKV0 7/20 0.59
▸ HDAC5 Q9UQL6 7/20 0.59
▸ HDAC3 O15379 6/20 0.59
▸ HDAC2 Q92769 6/20 0.59
▸ HDAC10 Q969S8 6/20 0.59
▸ CYP3A4 P08684 2/20 0.58
▸ KDM4E B2RXH2 1/20 0.58
▸ BRD4 O60885 1/20 0.58
▸ NCOR1 O75376 1/20 0.58

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Hydrochloric Acid SCHEMBL3353961 0.98 L3MBTL1 (0.70) L3MBTL1MAPTHTTSMN1; SMN2KDM1A
SCHEMBL608911 0.90 HDAC4 (0.66) L3MBTL1MAPTHTTHDAC4HDAC1
SCHEMBL10497217 0.90 HDAC6 (0.71) L3MBTL1HDAC4HDAC1HDAC7HDAC11
SCHEMBL3342586 0.89 L3MBTL1 (0.80) L3MBTL1MAPTHTTSMN1; SMN2HDAC4
SCHEMBL1433994 0.89 HDAC6 (0.74) HDAC4HDAC1HDAC7HDAC11HDAC8
SCHEMBL1065527 0.89 HDAC6 (0.74) HDAC4HDAC1HDAC7HDAC11HDAC8
SCHEMBL14966662 0.84 L3MBTL1 (1.00) L3MBTL1MAPTHTTSMN1; SMN2KDM1A
SCHEMBL94252 0.83 L3MBTL1 (0.89) L3MBTL1MAPTHTTSMN1; SMN2HDAC4
SCHEMBL1689279 0.83 KDM1A (0.69) L3MBTL1MAPTHTTSMN1; SMN2KDM1A
SCHEMBL4400398 0.83 L3MBTL1 (0.71) L3MBTL1MAPTHTTSMN1; SMN2KDM1A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 31 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-114249783-A Phenyl succinamide glycoside compound and preparation method and application thereof 山东省分析测试中心 2022-03-29 — — CN claimed
JP-2004502669-A — — 2004-01-29 — — JP claimed
EP-1377589-A1 OXAZOLYL-PYRAZOLE DERIVATIVES AS KINASE INHIBITORS Pharmacia Italia S.p.A. (IT) 2004-01-07 — — EP claimed
EP-1353898-A2 COMPOUNDS TO TREAT ALZHEIMER'S DISEASE Elan Pharmaceuticals, Inc. (US) 2003-10-22 — — EP claimed
WO-2002062804-A1 OXAZOLYL-PYRAZOLE DERIVATIVES AS KINASE INHIBITORS PHARMACIA ITALIA S.P.A. (IT) 2002-08-15 — — WO claimed
WO-2002002512-A2 COMPOUNDS TO TREAT ALZHEIMER'S DISEASE ELAN PHARMACEUTICALS, INC. (US) 2002-01-10 — — WO claimed
US-11911353-B2 Fatty acid synthase inhibitor and application thereof JIANGNAN UNIVERSITY (CN) 2024-02-27 — — US disclosed
US-11911353-B2 Fatty acid synthase inhibitor and application thereof JIANGNAN UNIVERSITY (CN) 2024-02-27 — — US disclosed
CN-114249783-B Phenyl butanediamide glycoside compound and preparation method and application thereof 北京东方红航天生物技术股份有限公司 2023-09-01 — — CN disclosed
CN-114249783-A Phenyl succinamide glycoside compound and preparation method and application thereof 山东省分析测试中心 2022-03-29 — — CN disclosed
CN-114249783-A Phenyl succinamide glycoside compound and preparation method and application thereof 山东省分析测试中心 2022-03-29 — — CN disclosed
CN-112299938-B Method for preparing amine compound by reducing amide compound 中国科学院兰州化学物理研究所 2021-12-28 — — CN disclosed
CN-110354110-B Lipase inhibitor and application thereof 江南大学 2021-03-12 — — CN disclosed
WO-2007094513-A2 CYCLIC AMINE COMPOUND AND USE THEREOF FOR THE PROPHYLAXIS OR TREATMENT OF HYPERTENSION TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2007-08-23 — — WO disclosed
US-7214715-B2 Compounds to treat Alzheimer's disease PHARMACIA & UPJOHN (US) 2007-05-08 — — US disclosed
US-7176242-B2 N,N′-substituted-1,3-diamino-2-hydroxypropane derivatives ELAN PHARMACEUTICALS, INC. (US) 2007-02-13 — — US disclosed
US-20060106256-A1 Substituted hydroxyethylamines PHARMACIA & UPJOHN COMPANY 2006-05-18 — — US disclosed
EP-0382548-B1 Thermoplastic resin composition SUMITOMO CHEMICAL CO (JP) 1994-06-29 — — EP disclosed
US-5116906-A Molding materials SUMITOMO CHEMICAL CO., LTD. (JP) 1992-05-26 — — US disclosed
EP-0382548-A2 Thermoplastic resin composition SUMITOMO CHEMICAL COMPANY, LIMITED (JP) 1990-08-16 — — EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-11911353-B2 Fatty acid synthase inhibitor and application thereof FASN, SCD, FADS2 L3MBTL1 2597/4885MAPT 4602/4885HTT 4757/4885
US-20060106256-A1 Substituted hydroxyethylamines HNMT, PNMT, BCHE L3MBTL1 944/4885MAPT 43/4885HTT 5/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.